Novartis Ag

University of Pennsylvania

Sunshine Lake Pharma Co., Ltd.

Jiquan Zhang

Qilong Wu

Michael C Milone

Jennifer Brogdon

David Jonathan Glass

Joan Mannick

Leon Murphy

Hilmar Erhard Ebersbach

Julia Jascur

Saar Gill

Thomas Huber

Yongqiang Wang

Reshma Singh

Huijuan Song

Celeste Richardson

Saad Kenderian

Andreas Loew

David L Porter

Marco Ruella

Lai Wei

Qiumei Yang

Carl H June

Yingjun Zhang

Lu Zhang

Jiancun Zhang

Bing Liu

Avery D Posey

Weihong Zhang

Jinlei Liu

Jihyun Lee

Michael Daley

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Treatment of cancer using a CD33 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Treatment of cancer using a CLL-1 chimeric antigen receptor

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Aminoquinazoline derivatives and their salts and methods of use

Growing community of inventors

Shanghai, China

Jiquan Zhang